Du är här

2014-05-22

InvestmentPitch: Mackie Research Updates Coverage on Tribute Pharmaceuticals Canada (OTCQB:TBUFF) with Speculative Buy Recommendation - Video Research Alert on

Vancouver, BC, May 22, 2014 - Investment firm Mackie Research has updated
coverage on Tribute Pharmaceuticals Canada (OTCQB:TBUFF). Analyst Andre
Uddin gives the company a speculative buy recommendation and reiterated his
12-month target of CDN$1.85, a premium of 176% to the US$0.60 price on May
15th, the day the report was issued.

InvestmentPitch.com has produced a "video research alert" about Tribute Pharma
based on this report. If this link is not enabled, please
visitwww.InvestmentPitch.comand enter "tribute" in the search box.

Tribute is a Canadian specialty pharmaceutical company focused on the
acquisition, licensing, development and management of pharmaceutical and
healthcare products with its primary focus on the Canadian and U.S. market.

The company targets several therapeutic areas, but has a particular interest
in products for the treatment of pain, dermatology, urology, endocrinology
and specialty care.

Rob Harris, President and CEO stated, "We are pleased with our performance in
the first quarter of 2014. With
Tribute's recently expanded sales force now established, our objectives for
upcoming quarters are to continue boosting sales of all our promoted products
in Canada while also introducing new products in this market.
"

Management and the board own 57% of the company, with Rob Harris, the CEO and
President, and Scott Langille, the CFO, having more than 55 years of combined
pharmaceutical industry experience.

Analyst Andre Uddin stated, "We expect sales growth and margins to improve,
which should drive the company
to be cash flow neutral by year end and positive in 2015. Any additional
products in-licensed would be expected to be accretive.
"

The shares are currently trading at US$0.54, well below Mackie Research's
target price of CDN$1.85, and with 51.4 million shares outstanding, the
company is capitalized at US$95 million.

For more information, please visit the company's websitewww.tributepharma.com,
or contact Scott Langille, CFO at 905-876-3166, or by email
atscott.langille@tributepharma.com.

Investor relations is handled by Kevin Fickle at Nuwa Group. He can be reached
at 925-330-8315, or emailkevin@nuwagroup.com.

For more information about Mackie Research, or to obtain the report on Tribute
Pharma, contact your nearest Mackie Research office. Their branches are
listed on their website atwww.mackieresearch.com.

About InvestmentPitch

InvestmentPitch.com, a multimedia company that provides a combined solution
for creating and hosting financial video content, and distributing it across
multiple platforms to investors and financial professionals, specializes in
producing corporate interviews and three minute videos based on news releases
and research reports. Please visit InvestmentPitch.com and browse our
extensive library of investment videos.

CONTACT:
InvestmentPitch.com
Barry Morgan, CFO
604-684-5524
bmorgan@investmentpitch.com

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: InvestmentPitch via Globenewswire

HUG#1788073

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.